Tacrolimus-associated posterior reversible Encephalopathy syndrome in allogenic Hematopoietic stem cell transplant

Authors

Hina Imtiaz, Aga Khan University, Karachi
Maryam Jamil Syed, Aga Khan University, Karachi
Dureshahwar Kanwar, Aga Khan University, Karachi
Bushra Taimuri, Aga Khan University Karachi
Sajid Hameed, Aga Khan University, Karachi

Document Type

Original Article

Abstract

Tacrolimus is an immunosuppressive drug used to lower the risk of transplant rejection in individuals after solid organ or hematopoietic transplantation. Cases of posterior reversible encephalopathy syndrome (PRES) as a complication of tacrolimus therapy are infrequently documented. The pathogenesis of this phenomenon is not well understood. Here, we report a case of an 18-year-old female with a history of acute myeloid leukemia that developed PRES after undergoing an allogeneic stem cell transplant and subsequent immunosuppressive therapy with tacrolimus.

Recommended Citation

Imtiaz, Hina; Jamil Syed, Maryam; Kanwar, Dureshahwar; Taimuri, Bushra; and Hameed, Sajid (2019) "Tacrolimus-associated posterior reversible Encephalopathy syndrome in allogenic Hematopoietic stem cell transplant," Pakistan Journal of Neurological Sciences (PJNS): Vol. 14: Iss. 3, Article 8.
Available at: https://ecommons.aku.edu/pjns/vol14/iss3/8